Immunitas Therapeutics procures $58m Series B

Immunitas Therapeutics, a single cell genomics-based therapeutics company, has secured $58 million in Series B financing.

To view this content, you need to sign in.

You should only be asked to sign in once. Not the case? Click here

Register now to access this content and more for free.

Share this